Skip to main content

Tagged With "Certification Program"

Blog Post

Dupixent® Shows Positive Results in Phase 3 of Trial for Ages 6 to 11 With Severe Atopic Dermatitis

AAFA Community Services ·
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that a pivotal Phase 3 trial evaluating Dupixent® (dupilumab) to treat severe atopic dermatitis in children aged 6 to 11 years met its primary and secondary endpoints. Dupixent is the first and only biologic to show positive results in this pediatric atopic dermatitis population.
Blog Post

Elijah E. Cummings Family Asthma Act Would Expand Efforts to Improve Care for People With Asthma

AAFA Community Services ·
Representatives Eliot L. Engel (D-NY-16), Fred Upton (R-MI-06), Pete King (R-NY-02) and TJ Cox (D-CA-21), all members of the House Asthma and Allergy Caucus, have introduced legislation to honor Elijah E. Cummings’ long-time advocacy for those living with asthma. The Elijah E. Cummings Family Asthma Act would expand federal, state, and local efforts to improve care for individuals with asthma.
Blog Post

EPA Works to Reduce Air Pollution in 32 States by Improving Older School Buses

AAFA Community Services ·
Today, the U.S. Environmental Protection Agency (EPA) awarded more than $8.7 million to replace or retrofit 452 older diesel school buses. The funds are going to 141 school bus fleets in 32 states, each of which will receive rebates through EPA's Diesel Emissions Reduction Act (DERA) funding. The new and retrofitted buses will reduce pollutants that are linked to health problems such as asthma and lung damage.
Blog Post

Fact or Fiction: 5 Myths About Dust Mites

AAFA Community Services ·
If you're reading this, there's a good chance you're one of the millions of Americans with a dust mite allergy. But how well do you know these microscopic creatures? Here's a look at some common misconceptions about dust mites and dust mite allergy.
Blog Post

FDA Approves Dupixent® for Treatment of Asthma

AAFA Community Services ·
The FDA has approved another biologic treatment, Dupixent, for the treatment of both moderate and severe asthma patients with eosinophilic phenotype and oral corticosteroid-dependent asthma, regardless of phenotype.
Blog Post

FDA Approves Dupixent® for Moderate-to-Severe Atopic Dermatitis in Adolescents

AAFA Community Services ·
Regeneron Pharmaceuticals, Inc. and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Dupixent® (dupilumab) for adolescent patients 12 to 17 years of age with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Dupixent can be used with or without topical corticosteroids.
Blog Post

FDA Approves First Generic ADVAIR DISKUS® for Asthma Treatment

AAFA Community Services ·
The U.S. Food and Drug Administration today approved the first generic of Advair Diskus (fluticasone propionate and salmeterol inhalation powder) for the twice-daily treatment of asthma in patients aged four years and older and maintenance treatment of airflow obstruction and reducing exacerbations in patients with chronic obstructive pulmonary disease (COPD).
Blog Post

FDA Approves Generic of Proventil HFA Albuterol Inhaler to Meet Demand Due to COVID-19

AAFA Community Services ·
The U.S. Food and Drug Administration today approved the first generic of Proventil HFA (albuterol sulfate) Metered Dose Inhaler, 90 mcg/Inhalation, for the treatment or prevention of bronchospasm in patients four years of age and older who have reversible obstructive airway disease, as well as the prevention of exercise-induced bronchospasm in this age group.
Blog Post

FDA Approves ProAir HFA Generic, a Quick-Relief Medicine for Asthma

AAFA Community Services ·
The U.S. Food and Drug Administration today approved the first generic of ProAir HFA (albuterol sulfate) Inhalation Aerosol for the treatment or prevention of bronchospasm in patients four years of age and older with reversible obstructive airway disease and the prevention of exercise-induced bronchospasm in patients four years of age and older.
Blog Post

FDA Approves Removal of Asthma-Related Death Box Warnings From Certain Asthma Medicines

AAFA Community Services ·
FDA's most prominent warning, the Boxed Warning, about asthma-related death has been removed from the drug labels of medicines that contain both an ICS and LABA. A FDA review of four large clinical safety trials shows that treating asthma with long-acting beta agonists (LABAs) in combination with inhaled corticosteroids (ICS) does not result in significantly more serious asthma-related side effects than treatment with ICS alone.
Blog Post

FDA Approves Spiriva Respimat to Treat Asthma In Children Ages 6-12

AAFA Community Services ·
[Press Release] FDA Expands Approval of SPIRIVA® RESPIMAT® (tiotropium bromide) Inhalation Spray for Maintenance Treatment of Asthma in Children Steroid-free SPIRIVA RESPIMAT now approved as asthma treatment for age 6 and older Supplemental New Drug Application (sNDA) approved under priority review from the FDA FDA also granted pediatric exclusivity to SPIRIVA RIDGEFIELD, Conn., Feb. 16, 2017 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and...
Blog Post

FDA Approves Symbicort to Treat Asthma In Children Ages 6-12

AAFA Community Services ·
AstraZeneca announced that the US Food and Drug Administration (FDA) approved SYMBICORT® (budesonide/formoterol fumarate dihydrate) Inhalation Aerosol 80/4.5 micrograms for the treatment of asthma in pediatric patients aged six up to 12 years.
Blog Post

FDA Approves Two New Asthma Inhalers

AAFA Community Services ·
[Press Release] Teva Announces FDA Approval of Two New RespiClick® Maintenance Inhalers for the Treatment of Asthma Approvals Expand Portfolio of Respiratory Medicines Delivered in RespiClick® Inhaler Designed to Eliminate the Need for Hand-Breath Coordination During Inhalation JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) announced that the U.S. Food and Drug Administration (FDA) approved two products for adolescent and adult patients with asthma.
Blog Post

FDA Considers Biologic Dupilumab for Children Ages 6 to 11 Years With Moderate-to-Severe Atopic Dermatitis

AAFA Community Services ·
Regeneron Pharmaceuticals, Inc. and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for Dupixent® (dupilumab) as an add-on maintenance treatment for children aged 6 to 11 years with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.
Blog Post

FDA Warns of Fraudulent and Unapproved Flu Products

AAFA Community Services ·
As part of the U.S. Food and Drug Administration’s ongoing efforts to protect consumers from health fraud, the agency is reminding consumers to be wary of unapproved products claiming to prevent, treat or cure influenza, or flu. This year’s severe flu season raises new concerns about the potential for consumers to be lured into buying unproven flu treatments, and even worse, buying counterfeit antivirals online from websites that appear to be legitimate online pharmacies.
Blog Post

February Advocacy Update: Over-the-Counter Medicines, Restaurant Safety and Cleaner Cars

Jenna R. ·
Welcome to your February advocacy update. I’m Jenna Riemenschneider, director of advocacy at the Asthma and Allergy Foundation of America (AAFA). I am pictured above with AAFA board member Renuka Babu Brown and Senator Ed Markey's (D-MA) policy advisor Adam Axler. Over-the-Counter Drug Access and Cleaner Cars Rollbacks AAFA and other members of the Healthy Choices Coalition met with Representative Judy Chu's office. We asked her to co-sponsor the Restoring Access to Medication Act of 2019...
Blog Post

Five Tips for Better Asthma and Allergy Health This Fall

AAFA Community Services ·
The Coalition for Medicare Choices and the Asthma and Allergy Foundation of America created this Pocket Companion to help improve respiratory health.
Blog Post

GlaxoSmithKline Study Shows Nucala Improves Quality of Life, Lung Function in Severe Asthma

AAFA Community Services ·
GlaxoSmithKline plc (LSE/NYSE:GSK) today announced data demonstrating that severe asthma patients, whose disease is driven by eosinophilic inflammation, treated with first-in-class biologic Nucala® (mepolizumab) added-on to standard of care, achieved clinically and statistically significant improvements in their health-related quality of life and lung function, when compared to patients treated with placebo and standard of care. These results are from the phase IIIb MUSCA study (NCT02281318, 200
Blog Post

GSK to Offer Generic Version of Ventolin HFA Albuterol Inhaler

AAFA Community Services ·
The Asthma and Allergy Foundation of America is sharing this press release from GlaxoSmithKline to bring you the latest research news quickly. [PRESS RELEASE] GSK announces availability of Authorized Generic Albuterol Sulfate Inhaler for treatment or prevention of bronchospasm Effective, January 15, 2019, GSK announced the availability of an authorized generic (AG) of Ventolin HFA (albuterol sulfate) inhalation aerosol. The AG will be manufactured by GSK and distributed by Prasco LLC. The...
Blog Post

Health Insurance 101 for People With Asthma and Allergies (Video and Resources)

AAFA Community Services ·
The Asthma and Allergy Foundation of America (AAFA) hosted a webinar on Thursday, March 30, 2017, about Health Insurance 101 for People with Asthma and Allergies. Watch video on YouTube Our guest speaker was Prue Fitzpatrick, MPH, a member of the Board of Directors for AAFA. She has a background in health care policy, having been involved with recent health reform policy development and implementation, as well as experience working within the insurance industry. Ms. Fitzpatrick discussed:...
Blog Post

Healthier Home Initiative Addresses Philadelphia’s Asthma Crisis

AAFA Community Services ·
The asthma & allergy friendly® Certification Program partnered with the Children’s Hospital of Philadelphia to help 30 families in the region improve their indoor home environment.
Blog Post

Helping Doctors Provide Personalized Asthma Care – the CHAMPS Project

AAFA Community Services ·
Many consider personalized medicine the future of health care, and for good reason. As we learn about patients, genetics and diseases, we see that a standard approach is not the best. The purpose of personalized medicine is to provide custom treatment plans for patients. While customized care can help patients, it also adds challenges due to many factors that influence asthma.
Blog Post

House Representatives Introduce Resolution to Have May Declared National Asthma and Allergy Awareness Month

AAFA Community Services ·
To mark World Asthma Day, Representatives Eliot L. Engel (NY-16) and Fred Upton (MI-6) have introduced a bipartisan House Resolution designating the month of May as “National Asthma and Allergy Awareness Month.”
Blog Post

How Do You Track Air Quality for Better Asthma Management?

AAFA Community Services ·
It should come as no surprise that the quality of the air we breathe affects our lungs. According to several studies, air pollution can make asthma symptoms worse. It’s also linked to higher asthma-related emergency room visits among senior adults and higher asthma rates in children.
Blog Post Featured

Patient Involvement in Asthma Research Creates New and Better Treatments

AAFA Community Services ·
The Asthma and Allergy Foundation of America (AAFA) believes your voice is valuable part of asthma research. And we want to empower people with asthma, caregivers and health care providers to take an active role in research. Promoting Asthma Patient Engagement in Research (PAPER) is a new research project from AAFA and the Patient-Centered Outcomes Research Institute (PCORI). Through this project, you can influence research that improves asthma understanding and treatment.
Blog Post

Pledge Your #TealLove to Someone With Asthma or Allergies This Valentine's Day

AAFA Community Services ·
Valentine's Day can be a challenge for people with allergies and asthma. Many traditional gifts and activities can be allergy and asthma triggers. #TealLove means choosing gifts that are allergy- and asthma-friendly. How can you pledge your #TealLove to someone with asthma and allergies on Valentine's Day? Show your asthma and allergy awareness with our #TealLove awareness image. Download the image to use as your profile pic and share on social media. Choose asthma- and allergy-friendly...
Blog Post

Promacta® Oral Suspension Recalled for Possible Peanut Contamination

AAFA Community Services ·
Novartis today announced a voluntary recall of three lots of Promacta (eltrombopag) 12.5 mg for oral suspension to the consumer level. The oral suspension lots are being recalled because of a risk of potential peanut flour contamination that occurred at a third-party contract manufacturing site.
Blog Post

Protect Yourself From Dust Mites With Asthma and Allergy Friendly Pillows and Pillow Covers

AAFA Community Services ·
When you lay your head on your pillow at night, all you want to think about is comfort – not millions of dust mites. And if you have a dust mite allergy, having all those microscopic insects near your head can make you uncomfortable by triggering allergy and asthma symptoms. You can create a healthier sleeping environment by using pillows that are CERTIFIED asthma & allergy friendly®. Or you can cover your existing pillow in a CERTIFIED pillow cover.
Blog Post

Questions About Eczema? Learn More During This Live Online Event

AAFA Community Services ·
On Nov. 8, 2018, from 3-4 p.m. ET, join us for a free interactive video program on eczema. The live session will include interactive polling, real-time question-and-answer session and an expert panel featuring specialists on eczema.
Blog Post

Recall Alert: Apotex Fluticasone Propionate Nasal Spray for Glass Particles

AAFA Community Services ·
Apotex Corp. Issues Voluntary Nationwide Recall of Fluticasone Propionate Nasal Spray USP 50 mcg Per Spray 120 Metered Sprays Due to Potential for Small Glass Particles
Blog Post

School-Based Respiratory Health Management Act Introduced to House

AAFA Community Services ·
[Press Release] Roe, Hoyer Introduce School-Based Respiratory Health Management Act Washington, May 2, 2017 | Lani Short (202-225-6356) WASHINGTON, DC – Today, Rep. Phil Roe, M.D. (R-TN) and House Democratic Whip Steny H. Hoyer (D-MD) introduced H.R. 2285, the School-Based Respiratory Health Management Act, legislation that encourages states to help ensure students with reversible lower airway disorders, such as asthma, have assistance at school with managing their chronic disease and can...
Blog Post

September/October Asthma and Allergy Advocacy Update: Passenger Rights on Planes, Protections in Schools and Access to OTC Medicines

Jenna R. ·
Welcome to our first monthly advocacy update. My name is Jenna Riemenschneider, Director of Advocacy at the Asthma and Allergy Foundation of America (AAFA). I'm pictured above with Mark Vieth, Senior Vice President at Cavarocchi Ruscio Dennis Associates, at a meeting with Airlines for America. Through this monthly blog series, I will update you on our advocacy efforts. We have already had a busy fall. This first post will include our September and October activity.
Blog Post

Share a Selfie for a Chance to Make Your Home More Asthma and Allergy Friendly

AAFA Community Services ·
Announcing the 2018 Certification sweepstakes! Upload a picture or a selfie of the CERTIFIED asthma & allergy friendly® Mark on a product or service on the asthma & allergy friendly® Certification Program's Facebook page for a chance to win.
Blog Post

Spring Cleaning for an Asthma and Allergy Friendly Home

AAFA Community Services ·
Give your home a spring cleaning with asthma and allergies in mind. Use this checklist to reduce allergens and triggers in each room of your home. CERTIFIED asthma & allergy friendly® products can help you improve the air quality in your home.
Blog Post

Study Shows Anti-Viral Medicine Reduces Flu Symptoms in People With High-Risk Conditions, Like Asthma

AAFA Community Services ·
Genentech, a member of the Roche Group, today announced that the Phase III CAPSTONE-2 study assessing the safety and efficacy of baloxavir marboxil in people at high risk of complications from the flu met the study’s primary objective, and showed superior efficacy in the primary endpoint of time to improvement of influenza symptoms versus placebo.
Blog Post

Study Shows How One Hospital Ensured Children Went Home with Asthma Medicine

AAFA Community Services ·
What health issue did the study examine? Families who leave a hospital with prescriptions for asthma medicine sometimes do not fill them. That can cause return trips to the emergency room for treatment. What do we know about this issue so far? Some families have trouble filling prescriptions after a hospital visit because of a lack of transportation, time or health insurance. Some hospitals have given patients medicine before they leave in an effort to reduce the number of return visits and...
Blog Post Featured

Tech Is a Good Prescription for People with Asthma and Allergies

AAFA Community Services ·
AAFA's new web platforms are designed with a fresh, clean and user-friendly design.
Blog Post

Without Funding, Millions of Children Could Lose Health Care Coverage From CHIP Program

AAFA Community Services ·
The Asthma and Allergy Foundation of America (AAFA) supports a five-year re-authorization of funding for the Children’s Health Insurance Program (CHIP) without offsetting cuts (pay-fors) to other programs that benefit children. CHIP is a bipartisan success story that should be celebrated. The program was created in 1997 and has been championed by lawmakers on both sides of the aisle since its beginning.
Blog Post

Teva Announces FDA Approval of QVAR® RediHaler™ Inhaler

AAFA Community Services ·
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that the U.S. Food and Drug Administration (FDA) has approved QVAR® RediHaler™ (beclomethasone dipropionate HFA) inhalation aerosol, a breath-actuated inhaler for the maintenance treatment of asthma as a prophylactic therapy in patients 4 years of age and older.
Blog Post

Teva Launches AirDuo™ RespiClick® and its Authorized Generic

AAFA Community Services ·
[Press Release] Teva Launches AirDuo™ RespiClick® and its Authorized Generic, Two Inhalers Containing Fluticasone Propionate and Salmeterol First and Only Generic Fluticasone Propionate and Salmeterol (ICS/LABA) Inhaler Available in the U.S. JERUSALEM, April 20, 2017 – Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced the simultaneous launch of AirDuo™ RespiClick® (fluticasone propionate and salmeterol) inhalation powder and its authorized generic for the treatment...
Blog Post

Texas Schools Suspend Students After Saving Classmates from Asthma Attacks

AAFA Community Services ·
Usually, we reward Good Samaritans coming to the aid of another human being who is sick - not punish them.
Blog Post

The asthma & allergy friendly™ Certification Program App Is Here!

AAFA Community Services ·
If you manage asthma or allergies, you strive to make your home the healthiest it can be. That's why the asthma & allergy friendly™ Certification Program has launched the Certification Program App. This free app is the first of its kind, and will help you make smart, informed choices on the best products for your family.
Blog Post

The Concerning Rise of Youth Vaping and What States Can Do to Help

AAFA Community Services ·
Vaping is causing serious lung disease in many teens. Yet, youth vaping continues to rise at an alarming rate. State policies can help curb youth vaping. As part of our 2019 State Honor Roll™ of Asthma and Allergy Policies for Schools (SHR), we look at the rise of vaping among our youth and what states can do to reduce rates.
Blog Post

Understanding Asthma Research: Get Involved

AAFA Community Services ·
Asthma research methods have been changing during the past several years. Research is more effective when researchers and patients work together to better understand asthma and find new treatments. At the Asthma and Allergy Foundation of America (AAFA), we feel your voice is valuable in asthma research. We support efforts to help you be an active part of the future of asthma management and treatments.
Blog Post

Understanding Asthma Research: How Research Is Prioritized

AAFA Community Services ·
We need asthma research so experts can find and create new treatments for asthma, and hopefully a cure. Experts decide what research is needed by looking at the effects of asthma.
Blog Post

Understanding Asthma Research: Informed Consent

AAFA Community Services ·
Some people are hesitant to participate in research. This may be because of fear of the unknown or from past stories. But today, patients have rights to protect them during research studies. Before you join a study, you will asked to sign an informed consent document.
Blog Post

Understanding Asthma Research: The National Institutes of Health

AAFA Community Services ·
When you hear about medical research, you probably hear about an organization called the NIH. The NIH is the United States’ medical research agency. It is also one of the top medical research agencies in the world.
Blog Post

Understanding Asthma Research: Working With Your Health Care Providers

AAFA Community Services ·
When you have asthma, you may have different health care providers who help you manage your asthma. These may include a primary care doctor, specialists and other experts who oversee parts of your treatment plan. Since proper asthma management is key, you need to understand each one’s focus and the role they play in your care. This is the first step toward building a partnership with your health care team for the best quality of life possible.
Blog Post

Understanding Your Asthma Diagnosis: Provocation Tests

AAFA Community Services ·
There are several types of lung function tests. If your doctor wants to see how sensitive your lungs are, they may have you do a provocation (proh-voh-KA-shun) test. It is also called a challenge or a trigger test.
Blog Post

Understanding Your Asthma Diagnosis: Spirometry

AAFA Community Services ·
Asthma is a chronic disease that causes you to have inflammation in your airways. Doctors use lung function tests to see how your lungs function or to see if you have inflammation. Spirometry is one of the most common lung function tests.
×
×
×
×